BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. Co. leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the U.S.. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. We show 65 historical shares outstanding datapoints in our BCRX shares outstanding history coverage, used to compute BCRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BCRX market cap history over the course of time is important for investors
interested in comparing BCRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BCRX versus a peer is one thing; comparing
BCRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BCRX can fluctuate over the course of history.
With this page we aim to empower investors researching BCRX by allowing them to research the BCRX market cap history. |
Free BCRX Email Alerts:
Video: The Importance of Market Cap
